A5079242896- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- Immune cells in cancer
- Chemokine receptors and signaling
- Monoclonal and Polyclonal Antibodies Research
- Virus-based gene therapy research
- Cytokine Signaling Pathways and Interactions
- SARS-CoV-2 and COVID-19 Research
- RNA modifications and cancer
- RNA and protein synthesis mechanisms
- Galectins and Cancer Biology
- COVID-19 Clinical Research Studies
- Ferroptosis and cancer prognosis
- Phagocytosis and Immune Regulation
- Health Systems, Economic Evaluations, Quality of Life
- Hepatitis C virus research
- Public Health in Brazil
- SARS-CoV-2 detection and testing
- vaccines and immunoinformatics approaches
- Advanced biosensing and bioanalysis techniques
Navarre Institute of Health Research
2018-2023
Universidad de Navarra
2018-2023
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2020-2023
Interleukin-8 (CXCL8) produced in the tumor microenvironment correlates with poor response to checkpoint inhibitors and is known chemoattract activate immunosuppressive myeloid leukocytes. In human cancer, IL8 mRNA levels correlate IL1B TNF transcripts. Both cytokines induced IL-8 functional expression from a broad variety of cancer cell lines, primary colon carcinoma organoids, fresh explants. Although absent mouse genome, similar murine axis which TNFα IL-1β upregulate CXCL1 CXCL2 cells...
Interleukin-12 (IL-12) gene transfer enhances the therapeutic potency of adoptive T cell therapies. We previously reported that transient engineering tumor-specific CD8 cells with IL-12 mRNA enhanced their systemic efficacy when delivered intratumorally. Here, we mix engineered mRNAs to express either single-chain (scIL-12) or an IL-18 decoy-resistant variant (DRIL18) is not functionally hampered by binding protein (IL-18BP). These mRNA-engineered mixtures are repeatedly injected into mouse...
Abstract The ability of conventional type-1 dendritic cells (cDC1) to cross-present tumor antigens CD8+ T is critical for the induction antitumor CTLs. Mice that are constitutively deficient in cDC1 have been reported fail respond immunotherapy strategies based on checkpoint inhibitors. However, further work needed clarify precise time during treatment required beneficial effect treatment. Here, we used a refined XCR1-DTR-Venus transgenic mouse model acutely deplete and trace their behavior...
Background Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not investigated. Our aim was analyze whether tumors in HCC patients contain neoantigens suitable future use therapeutic Methods Whole-exome sequencing RNAseq were performed cohort of fourteen submitted surgery...
IL12-based local gene therapy of cancer constitutes an active area clinical research using plasmids, mRNAs, and viral vectors. To improve antitumor effects, we have experimentally tested the combination mRNA constructs encoding IL12 IL18. Moreover, used a form IL18 [decoy-resistant (DR-18)] which has preserved bioactivity but does not bind to binding protein decoy receptor. Both cytokines dramatically synergize induce IFNγ release from mouse splenocytes, and, if systemically cotransferred...
Therapies based on immune checkpoint inhibitors (ICPI) have yielded promising albeit limited results in patients with hepatocellular carcinoma (HCC). Vaccines been proposed as combination partners to enhance response rates ICPI. Thus, we analyzed the combined effect of a vaccine TLR4 ligand cold-inducible RNA binding protein (CIRP) plus Mice were immunized vaccines containing ovalbumin linked CIRP (OVA-CIRP), or without ICPI, and antigen-specific responses therapeutic efficacy tested...
Identification of relevant epitopes is crucial for the development subunit peptide vaccines inducing neutralizing and cellular immunity against SARS-CoV-2. Our aim was characterization in receptor-binding domain (RBD) SARS-CoV-2 spike (S) protein to generate a vaccine. Epitope mapping using panel 10 amino acid overlapped 15-mer peptides covering region 401-515 from RBD did not identify linear when tested with sera infected individuals or RBD-immunized mice. However, immunization mice these...
Current vaccines against SARS-CoV-2, based on the original Wuhan sequence, induce antibodies with different degrees of cross-recognition new viral variants concern. Despite potent responses generated in vaccinated and infected individuals, Omicron (B.1.1.529) variant causes breakthrough infections, facilitating transmission. We previously reported a vaccine cyclic peptide containing 446-488 S1 sequence (446-488cc) SARS-CoV-2 spike (S) protein from isolate. To provide best immunity Omicron,...
Vaccination using optimized strategies may increase response rates to immune checkpoint inhibitors (ICI) in some tumors. To enhance vaccine potency and improve thus responses ICI, we analyzed the gene expression profile of an immunosuppressive dendritic cell (DC) population induced during vaccination, with goal identifying druggable inhibitory mechanisms. RNAseq studies revealed targetable genes, but their inhibition did not result improved vaccines. However, proved that DC had a monocytic...
<div>Abstract<p>The ability of conventional type-1 dendritic cells (cDC1) to cross-present tumor antigens CD8<sup>+</sup> T is critical for the induction antitumor CTLs. Mice that are constitutively deficient in cDC1 have been reported fail respond immunotherapy strategies based on checkpoint inhibitors. However, further work needed clarify precise time during treatment required beneficial effect treatment. Here, we used a refined XCR1-DTR-Venus transgenic mouse model...
<p>Supplementary figures 1-5 Supplementary methods</p>
<div>Abstract<p>The ability of conventional type-1 dendritic cells (cDC1) to cross-present tumor antigens CD8<sup>+</sup> T is critical for the induction antitumor CTLs. Mice that are constitutively deficient in cDC1 have been reported fail respond immunotherapy strategies based on checkpoint inhibitors. However, further work needed clarify precise time during treatment required beneficial effect treatment. Here, we used a refined XCR1-DTR-Venus transgenic mouse model...
<p>video S1</p>
<p>video S1</p>
<p>Video S2</p>
<p>Video S2</p>
<p>Video S3</p>
<p>Video S3</p>
<p>Supplementary figures 1-5 Supplementary methods</p>
<div>Abstract<p>IL12-based local gene therapy of cancer constitutes an active area clinical research using plasmids, mRNAs, and viral vectors. To improve antitumor effects, we have experimentally tested the combination mRNA constructs encoding IL12 IL18. Moreover, used a form IL18 [decoy-resistant (DR-18)] which has preserved bioactivity but does not bind to binding protein decoy receptor. Both cytokines dramatically synergize induce IFNγ release from mouse splenocytes, and, if...